1. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308(6921):81106.
2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86.
3. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348(9038): 1329-1339.
4. Fox K.A., Mehta S.R., Peters R. et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110(10):1202-8.
5. Steinhubl S.R., Berger P.B., Mann J.T. 3rd et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288(19):2411-20.
6. Muller I., Besta F., Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89(5): 783-787.
7. Geisler T., Langer H., Wydymus M. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27(20): 2420–2425
8. Combescure C., Fontana P., Mallouk N. et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis.J ThrombHaemost 2010; 8(5): 923–933
9. Aleil B., Jacquemin L., De Poli F. et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 2008;1(6):631-8.
10. Cuisset T., Frere C., Quilici J. et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv 2008;1(6):649-53.
11. Zuern C.S., Schwab M., Gawaz M., Geisler T. Platelet Pharmacogenomics. J Thromb Haemost 2010;8(6):1147-58.
12. Simon T., Verstuyft C., Mary-Krause M. et al. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. N Engl J Med 2009;360(4):363-75.
13. Kim K.A., Park P.W., Hong S.J., Park J.Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008; 84(2): 236-42.
14. Mega J.L., Close S.L., Wiviott S.D. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360(4): 354-62.
15. Trenk D., Hochholzer W., Fromm M.F. et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51(10):1925-1934
16. Brandt J.T., Close S.L., Iturria S.J. et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5(12):2429-36.
17. HarmszeA., vanWerkumJ.W.,BoumanH.J. et al.BesidesCYP2C19*2,the variant alleleCYP2C9*3 is associatedwithhigheron-clopidogrelplateletreactivity inpatientsondual antiplatelettherapyun�dergoing elective coronary stent implantation. Pharmacogenet Genomics 2010;20(1):18-25.
18. Lau W.C., Gurbel P.A., Watkins P.B. et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrelresistance. Circulation 2004; 109(21): 166-71.
19. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E. et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006; 26(8): 1895-900.
20. Fontana P., Dupont A., Gandrille S. et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108(8): 989-995.
21. Ziegler S., SchillingerM., FunkM. et al.Association of a functional polymorphism in the clopidogrel targetreceptor gene, P2Y12, and the risk forischemic cerebrovascular events in patientswith peripheral artery disease. Stroke 2005: 36(7): 1394–1399.
22. Rudez G., BoumanH.J., vanWerkum J.W. et al. Common variation in the plateletreceptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ Cardiovasc Genet 2009;2(5):515-21.
23. Сироткина О.В., Богданова Е.В., Боганькова Н.А. и др. Эффективность антиагрегантной терапии клопидогрелом у пациентов, перенесших инфаркт миокарда с подъемом сегмента ST. Кардиоваскулярная терапия и профилактика 2009; 8(1): 51-55.
24. А.Б. Сумароков, Л.И. Бурячковская, М.В. Ежов, И.А. Учитель, Ю.В. Доценко. Особенности дезагрегантной терапии у больных ишемической болезнью сердца в сочетании с язвенной болезнью. Кардиоваскулярная терапия и профилактика, 2010; 9(51) 28-36.
